Enzymotec Ltd Company Profile (NASDAQ:ENZY)

About Enzymotec Ltd

Enzymotec Ltd logoEnzymotec Ltd. is a nutritional ingredients and medical foods company. The Company's technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company's segments offer a range of products that leverage its lipid-related offerings. Its product suite addresses the entire human life-cycle, from infancy to old age, and comprises ingredients in products ranging from infant formula to nutritional supplements, as well as branded medical foods, sold only under a doctor's supervision. It markets its product portfolio to established global consumer companies and physicians and target large and growing consumer health and wellness markets. The Company's clinically-validated products include bio-functional lipid-based compounds designed to address dietary needs, medical disorders and common diseases.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ENZY
  • CUSIP:
Key Metrics:
  • Previous Close: $9.05
  • 50 Day Moving Average: $8.29
  • 200 Day Moving Average: $7.25
  • 52-Week Range: $5.20 - $9.32
  • Trailing P/E Ratio: 84.58
  • Foreward P/E Ratio: 20.11
  • P/E Growth: 1.02
  • Market Cap: $205.97M
  • Outstanding Shares: 22,759,000
  • Beta: 1.26
  • Net Margins: 4.82%
  • Return on Equity: 1.95%
  • Return on Assets: 1.78%
  • Current Ratio: 7.40%
  • Quick Ratio: 5.00%
Additional Links:
Companies Related to Enzymotec Ltd:

Analyst Ratings

Consensus Ratings for Enzymotec Ltd (NASDAQ:ENZY) (?)
Ratings Breakdown: 3 Hold Ratings
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $8.00 (11.60% downside)

Analysts' Ratings History for Enzymotec Ltd (NASDAQ:ENZY)
DateFirmActionRatingPrice TargetDetails
2/23/2017Jefferies Group LLCReiterated RatingHold$8.00View Rating Details
11/17/2016Wells Fargo & CoDowngradeOutperform -> Market PerformView Rating Details
4/17/2016Canaccord GenuityReiterated RatingHoldView Rating Details
(Data available from 2/28/2015 forward)


Earnings History for Enzymotec Ltd (NASDAQ:ENZY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/22/2017Q416$0.03($0.10)$11.47 million$10.60 millionViewN/AView Earnings Details
11/16/2016Q316$0.07$0.03$13.29 million$11.40 millionViewN/AView Earnings Details
8/9/2016Q216$0.08$0.04$14.90 million$15.00 millionViewN/AView Earnings Details
5/19/2016Q116$0.05$0.09$13.85 million$14.00 millionViewListenView Earnings Details
2/17/2016Q415$0.10$0.07$14.01 million$13.30 millionViewListenView Earnings Details
11/11/2015Q315$0.07$0.08$14.21 million$12.40 millionViewListenView Earnings Details
8/12/2015Q215$0.06$0.11$12.39 million$13.40 millionViewListenView Earnings Details
5/7/2015Q115$0.06$0.09$12.10 million$12.25 millionViewN/AView Earnings Details
2/18/2015Q414$0.08$0.06$11.11 million$10.80 millionViewN/AView Earnings Details
11/13/2014Q314$0.04$0.05$10.22 million$9.50 millionViewN/AView Earnings Details
8/5/2014Q214$0.10$0.02$14.88 million$11.50 millionViewN/AView Earnings Details
5/14/2014Q114$0.17$0.24$19.40 million$23.70 millionViewN/AView Earnings Details
2/13/2014Q413$0.11$0.15$11.64 million$18.51 millionViewN/AView Earnings Details
11/11/2013Q313$0.11$0.13$13.10 million$22.50 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Enzymotec Ltd (NASDAQ:ENZY)
Current Year EPS Consensus Estimate: $0.30 EPS
Next Year EPS Consensus Estimate: $0.45 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161$0.05$0.05$0.05
Q2 20161$0.08$0.08$0.08
Q3 20161$0.06$0.06$0.06
Q4 20161$0.07$0.07$0.07
(Data provided by Zacks Investment Research)


Dividend History for Enzymotec Ltd (NASDAQ:ENZY)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Enzymotec Ltd (NASDAQ:ENZY)
No insider trades for this company have been tracked by MarketBeat.com


Latest Headlines for Enzymotec Ltd (NASDAQ:ENZY)
marketexclusive.com logoAnalyst Activity – Jefferies Group LLC Reiterates Hold on Enzymotec (NASDAQ:ENZY) (NASDAQ:ENZY)
marketexclusive.com - February 23 at 10:02 PM
sg.finance.yahoo.com logoEnzymotec reports 4Q loss (NASDAQ:ENZY)
sg.finance.yahoo.com - February 22 at 5:16 PM
newsmaker.com.au logoKrill Oil Market Would Reach $ 703.0 Mn By 2022 (NASDAQ:ENZY)
www.newsmaker.com.au - February 22 at 7:55 AM
News IconHow VAYA Pharma used Facebook ads for its ADHD campaign (NASDAQ:ENZY)
www.mmm-online.com - February 22 at 7:55 AM
reuters.com logoBRIEF-Enzymotec Q4 non-GAAP loss per share $0.10 (NASDAQ:ENZY)
www.reuters.com - February 22 at 7:55 AM
finance.yahoo.com logoEnzymotec Ltd. Reports Fourth Quarter and Full Year 2016 Unaudited Financial Results (NASDAQ:ENZY)
finance.yahoo.com - February 22 at 7:55 AM
News IconPharma Company Succeeds Using Social Media (NASDAQ:ENZY)
www.dmnews.com - February 17 at 5:50 PM
finance.yahoo.com logoENZY : Summary for Enzymotec Ltd. - Yahoo Finance (NASDAQ:ENZY)
finance.yahoo.com - February 13 at 10:51 PM
finance.yahoo.com logoEnzymotec Ltd. Announces Preliminary Fourth Quarter and Full Year 2016 Financial Results (NASDAQ:ENZY)
finance.yahoo.com - February 6 at 9:43 AM
openpr.com logoKrill Oil Market Anticipated to Grow at 12.9% CAGR by 2022 (NASDAQ:ENZY)
www.openpr.com - February 1 at 10:36 PM
openpr.com logoKrill Oil Market to Cross $703 Million By 2022, Globally (NASDAQ:ENZY)
www.openpr.com - January 25 at 3:47 AM
finance.yahoo.com logoCORRECTING and REPLACING -- Improved Academic Performance and Medication Rebound in Patients with ADHD … (NASDAQ:ENZY)
finance.yahoo.com - January 25 at 3:47 AM
openpr.com logoKrill Oil Market Will Reach US$ 703.0 Mn By 2022 (NASDAQ:ENZY)
www.openpr.com - January 23 at 9:22 AM
finance.yahoo.com logoPolyunsaturated Fatty Acids (PUFAs) Market: Rising Demand for Omega-3 and Omega-6 Fatty Acids Fuelling … (NASDAQ:ENZY)
finance.yahoo.com - January 11 at 5:33 PM
openpr.com logoKrill Oil Market to Rise at 12.9% CAGR by 2022, Globally (NASDAQ:ENZY)
www.openpr.com - January 3 at 12:19 PM
openpr.com logoKrill Oil Market is Anticipated to Increase to US$ 703.0 Million By 2022 (NASDAQ:ENZY)
www.openpr.com - December 29 at 5:05 PM
sbwire.com logoKrill Oil Industry - Detailed Study Analysis and Forecast (NASDAQ:ENZY)
www.sbwire.com - December 22 at 10:11 PM
News IconKrill Oil Industry – Detailed Analysis and Forecast (NASDAQ:ENZY)
empowerednews.net - December 22 at 10:11 PM
publicnow.com logo2016-12-21 Enzymatica AB: Top-line results of new clinical trial (NASDAQ:ENZY)
www.publicnow.com - December 21 at 9:37 AM
News IconPolyunsaturated Fatty Acids (PUFAs) Market expected to grow at a CAGR of 10.7% during 2016 to 2026 (NASDAQ:ENZY)
www.free-press-release-center.info - December 20 at 6:25 PM
publicnow.com logo2016-12-19 Enzymatica AB: Bulletin from extraordinary general meeting in Enzymatica AB (publ) (NASDAQ:ENZY)
www.publicnow.com - December 20 at 10:00 AM
openpr.com logoPolyunsaturated Fatty Acids (PUFAs) Market expected to grow at a CAGR CAGR of 10.7% During 2016-2026 (NASDAQ:ENZY)
www.openpr.com - December 16 at 5:31 PM
finance.yahoo.com logoWhat Makes Enzymotec (ENZY) a Strong Sell? (NASDAQ:ENZY)
finance.yahoo.com - December 12 at 11:52 AM
newsmaker.com.au logoKrill Oil Market will Hit at 12.9% CAGR by 2022, Globally (NASDAQ:ENZY)
www.newsmaker.com.au - December 2 at 5:17 PM
www.publicnow.com - December 1 at 5:04 PM
publicnow.com logo2016-12-01 Enzymatica AB: Extraordinary shareholders' meeting on changes to the board of directors (NASDAQ:ENZY)
www.publicnow.com - December 1 at 5:04 PM
capitalcube.com logoEnzymotec Ltd. :ENZY-US: Earnings Analysis: Q3, 2016 By the Numbers : November 28, 2016 (NASDAQ:ENZY)
www.capitalcube.com - November 29 at 5:28 PM
News IconKrill oil market to reach USD 720 million by 2023 according to new research report (NASDAQ:ENZY)
www.whatech.com - November 25 at 10:03 AM
finance.yahoo.com logoEnzymotec downgraded by Wells Fargo (NASDAQ:ENZY)
finance.yahoo.com - November 17 at 4:15 PM
4-traders.com logoEnzymotec Ltd :. Announces Departure of its CEO (NASDAQ:ENZY)
www.4-traders.com - November 17 at 6:25 AM
baystreet.ca logoEnzymotec (ENZY) Off on Prospective Earnings (NASDAQ:ENZY)
www.baystreet.ca - November 16 at 10:34 PM
finance.yahoo.com logoEdited Transcript of ENZY earnings conference call or presentation 16-Nov-16 1:30pm GMT (NASDAQ:ENZY)
finance.yahoo.com - November 16 at 10:34 PM
globenewswire.com logoEnzymotec Ltd. Announces Departure of its CEO (NASDAQ:ENZY)
globenewswire.com - November 16 at 8:01 AM
fxpips.com logoPre-Market Company Earnings Report, Nov. 16 (NASDAQ:ENZY)
www.fxpips.com - November 16 at 8:01 AM
finance.yahoo.com logoEnzymotec Ltd. Reports Third Quarter 2016 Unaudited Financial Results (NASDAQ:ENZY)
in.finance.yahoo.com - November 16 at 8:01 AM
reuters.com logoBRIEF-Enzymotec Ltd. announces departure of its CEO (NASDAQ:ENZY)
www.reuters.com - November 16 at 8:01 AM
sg.finance.yahoo.com logoEnzymotec reports 3Q loss (NASDAQ:ENZY)
sg.finance.yahoo.com - November 16 at 8:01 AM
sbwire.com logoGlobal Krill Oil Market: Western Europe Demanding Region (NASDAQ:ENZY)
www.sbwire.com - November 10 at 8:59 PM
News IconGrowth Predicted for the Global Krill Oil Market (NASDAQ:ENZY)
www.nutraceuticalsworld.com - November 10 at 8:59 PM
News IconGlobal Krill Oil Market is Expected to be Valued at US$ 703.0 Mn By 2022 (NASDAQ:ENZY)
www.mynewsdesk.com - November 9 at 1:59 PM
publicnow.com logo2016-11-03 Enzymatica AB: ColdZyme® sales continue to perform well (NASDAQ:ENZY)
www.publicnow.com - November 3 at 5:30 AM
publicnow.com logoEnzymotec to Report Third Quarter 2016 Financial Results (NASDAQ:ENZY)
www.publicnow.com - November 2 at 4:59 PM
publicnow.com logo2016-11-02 Enzymatica AB: Enzymatica signs distribution agreement with Endeavour Consumer Health (NASDAQ:ENZY)
www.publicnow.com - November 2 at 4:59 PM
openpr.com logoGlobal Krill Oil Market : Soft gel segment to reach at a CAGR of 13.4% by 2022 (NASDAQ:ENZY)
www.openpr.com - October 27 at 10:07 PM
News IconFEATURED MOVER | Niela Magwood-Phoenix, VAYA Pharma (NASDAQ:ENZY)
thedailyrecord.com - October 25 at 4:54 PM
News IconPhytosterols Market To Gain From Enhanced Demand In Various Application Sector As Cosmetics Till 2020: Grand View Research, Inc. (NASDAQ:ENZY)
www.abnewswire.com - October 24 at 10:04 AM
News IconNiela Magwood-Phoenix | Vaya Pharma (NASDAQ:ENZY)
thedailyrecord.com - October 4 at 9:41 AM
News IconKrill Oil Market driven by increasing health concerns among consumers (NASDAQ:ENZY)
www.medgadget.com - September 30 at 5:12 PM
4-traders.com logoNews Highlights : Top Financial Services News of the Day (NASDAQ:ENZY)
www.4-traders.com - September 28 at 4:44 PM
finance.yahoo.com logoEnzymotec Ltd. Granted New Patents for INFAT® in the U.S., Vayacog® in Japan and Phospholipid-Based Products in Canada and Korea (NASDAQ:ENZY)
finance.yahoo.com - September 27 at 9:25 AM


What is Enzymotec Ltd's stock symbol?

Enzymotec Ltd trades on the NASDAQ under the ticker symbol "ENZY."

Where is Enzymotec Ltd's stock going? Where will Enzymotec Ltd's stock price be in 2017?

3 equities research analysts have issued 1-year target prices for Enzymotec Ltd's stock. Their forecasts range from $8.00 to $8.00. On average, they anticipate Enzymotec Ltd's stock price to reach $8.00 in the next twelve months.

When will Enzymotec Ltd announce their earnings?

Enzymotec Ltd is scheduled to release their next quarterly earnings announcement on Wednesday, May, 17th 2017.

What are analysts saying about Enzymotec Ltd stock?

Here are some recent quotes from research analysts about Enzymotec Ltd stock:

  • Jefferies Group LLC analysts commented, "Enzymotec has been pressured by a shifting regulatory environment and lackluster demand even as it has accelerated investment in Vaya. Regulatory changes will continue to ripple through the supply chain in 2H17-2018. We expect shares to remain range-bound absent an improvement in end markets and sustained profitability in Vaya. Clarity around strategic opportunities in InFat and the pending CEO transition would help reduce its risk profile." (2/23/2017)
  • According to Zacks Investment Research, "Enzymotec, Ltd. provides specialty lipid-based products and solutions. The Company develops, manufactures and markets bio-functional lipid ingredients as well as final products. It serves pharmaceuticals and nutrition industries worldwide. Enzymotec, Ltd. is based in Migdal HaEmeq, Israel. " (1/17/2017)

Who owns Enzymotec Ltd stock?

Enzymotec Ltd's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Paulson & CO. Inc. (18.48%), Janus Capital Management LLC (1.27%), Renaissance Technologies LLC (1.27%), FMR LLC (0.37%), Menta Capital LLC (0.22%) and State Street Corp (0.09%).

Who sold Enzymotec Ltd stock? Who is selling Enzymotec Ltd stock?

Enzymotec Ltd's stock was sold by a variety of institutional investors in the last quarter, including Menta Capital LLC.

Who bought Enzymotec Ltd stock? Who is buying Enzymotec Ltd stock?

Enzymotec Ltd's stock was bought by a variety of institutional investors in the last quarter, including Paulson & CO. Inc., Renaissance Technologies LLC and State Street Corp.

How do I buy Enzymotec Ltd stock?

Shares of Enzymotec Ltd can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Enzymotec Ltd stock cost?

One share of Enzymotec Ltd stock can currently be purchased for approximately $9.05.

Enzymotec Ltd (NASDAQ:ENZY) Chart for Tuesday, February, 28, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for Enzymotec Ltd (NASDAQ:ENZY)

Earnings History Chart

Earnings by Quarter for Enzymotec Ltd (NASDAQ:ENZY)

Dividend History Chart

Dividend Payments by Quarter for Enzymotec Ltd (NASDAQ:ENZY)

Last Updated on 2/28/2017 by MarketBeat.com Staff